Compare ConocoPhillips (COP) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Heron Therapeutics Inc — how do they compare? ConocoPhillips trades at $125.84 (market cap $147.80B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: ConocoPhillips is far larger — about 2330.9× Heron Therapeutics Inc's market cap, and ConocoPhillips pays a 2.73% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| COP | HRTX | |
|---|---|---|
Market Cap | $147.80B | $63.41M |
Sector | Energy | Health |
52-Week High | $133.80 | $1.49 |
52-Week Low | $85.66 | $0.33 |
Enterprise Value | $163.40B | $161.31M |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $117.61, up 0.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $149.25. Recent Q2 2026 earnings beat expectations with EPS of $3.24 versus $2.90 estimated, driven by strong Permian Basin output and higher oil prices. The company reaffirmed its $7 billion free cash flow target by 2029 and completed a $1.7 billion asset sale ahead of schedule.
Outlook is positive due to robust operational performance and favorable oil market trends, but risks include commodity price volatility and CEO transition. The stock offers value with a P/E of 15.56 and a net income margin of 14.65%, supported by 74.51% analyst buy ratings.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
